UnitedHealthcare · Semaglutide · US health-plan appeal rights

Semaglutide denied as non-formulary by UnitedHealthcare?

Q: How long do I have to appeal a UnitedHealthcare Semaglutide denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Q: What does UnitedHealthcare typically require for Semaglutide coverage?

BMI >=30, OR BMI >=27 with at least one weight-related comorbidity (T2DM, hypertension, dyslipidemia, CVD, OSA). 6-month documented diet/exercise program. Step therapy: failed/contraindicated phentermine/topiramate or Contrave trial.

Non-formulary doesn't mean uncoverable. Most plans have a formulary-exception process: the appeal needs to show the formulary alternatives are inappropriate for your specific clinical situation.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-09

Policy data current as of 2026-05-04

At a glance

Why does UHC deny semaglutide as non-formulary?

The specific brand (Wegovy, Ozempic, Rybelsus) sits at a higher tier than the patient's plan covers. OptumRx typically prefers liraglutide/Saxenda or a different semaglutide formulation depending on plan year and contract.

How do I get semaglutide covered when it's non-formulary?

Submit a tier exception (not a formulary addition) via the OptumRx Tier Exception form. Argue medical necessity for THIS specific brand vs. covered alternatives — failure of preferred GLP-1, indication mismatch, or continuity of care.

What if the patient is stable on a non-preferred brand of semaglutide?

Federal continuity-of-care provisions under 45 CFR §156.122 require coverage continuation during the plan year for stable medications on ACA-compliant plans. Document the dates of stability.

Can I appeal on patient preference alone?

No — UHC reviewers reject preference-based exceptions automatically. Every tier exception argument must reduce to medical necessity for THIS brand vs. the formulary alternative.

How fast can the tier exception decision come?

7-day expedited review under ERISA §503(f)(2)(i) urgent-care provisions if the patient has <14 days remaining supply — bypasses the standard 30-day review window.

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What UnitedHealthcare typically requires

BMI >=30, OR BMI >=27 with at least one weight-related comorbidity (T2DM, hypertension, dyslipidemia, CVD, OSA). 6-month documented diet/exercise program. Step therapy: failed/contraindicated phentermine/topiramate or Contrave trial.

Source policy: GLP-1 Receptor Agonists for Weight Management

What works in the appeal

Step-therapy: Document contraindications to required agents - phentermine contraindicated in cardiovascular disease, uncontrolled hypertension, hyperthyroidism, glaucoma, MAOI use within 14 days (FDA prescribing information); phentermine/topiramate contraindicated in pregnancy, glaucoma, hyperthyroidism, MAOI use (FDA prescribing information); naltrexone/bupropion contraindicated in uncontrolled hypertension, seizure disorders, eating disorders, chronic opioid use, abrupt discontinuation of alcohol/benzodiazepines (FDA prescribing information). If prior trial completed: document inadequate response (weight loss <5% after 12 weeks per 2016 AACE/ACE obesity guidelines) or intolerance with specific adverse effects (e.g., tachycardia, insomnia, nausea, headache). Cite semaglutide 2.4mg FDA approval for chronic weight management in adults with obesity or overweight with weight-related comorbidity (June 2021). Reference STEP 1 trial showing semaglutide produced mean 14.9% body weight reduction vs 2.4% with placebo at 68 weeks (NEJM 2021;384:989-1002). Cite AMA recognition of obesity as a disease requiring treatment (2013) and 2016 AACE/ACE obesity algorithm supporting GLP-1 receptor agonists when lifestyle and first-line pharmacotherapy fail or are contraindicated. BMI threshold: Verify FDA indication (BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia). Supervised program: Document prior lifestyle intervention attempts including dietary counseling and increased physical activity per FDA indication requirements. Employer carve-out: Request plan documents confirming exclusion; appeal as medically necessary treatment for chronic disease; consider state parity laws if applicable.

The UnitedHealthcare angle on Semaglutide

UHC's non-formulary denial on semaglutide almost always means the specific brand (Wegovy, Ozempic, or Rybelsus) sits at a higher tier than the patient's plan covers. OptumRx's preferred GLP-1 varies by plan: liraglutide/Saxenda is preferred on some plans, a specific semaglutide formulation on others. The path is a tier exception, not a formulary addition request.

The distinction matters: tier exceptions argue medical necessity for this specific brand vs. covered alternatives. Formulary additions are policy-level requests that almost never succeed at the patient level.

Three argument lines that win UHC tier exceptions:

Failure of preferred GLP-1. If the patient tried Saxenda (daily injection) with severe injection-site reactions or GI intolerance despite dose titration, document the trial dates and the chart-cited reason for discontinuation. UHC accepts this as step failure within the GLP-1 class.
Indication mismatch. Wegovy and Ozempic are the same molecule, but Aetna sometimes covers one and not the other based on FDA-approved indication. If the patient has T2DM and Wegovy is being prescribed (obesity indication only), the tier exception fails — request Ozempic instead (T2DM-approved). If the patient has obesity without T2DM, Ozempic prescribed off-label fails on a different ground; request Wegovy.
Dosing schedule. Wegovy and Ozempic share the molecule but have different titration schedules. If the patient was stabilized on a specific titration, switching disrupts response. Cite the titration as clinically necessary.

UHC's OptumRx tier exception form requires a Prescriber Statement of Medical Necessity with specific check-boxes. Use the form, not a free-text letter — free-text letters get bounced back as non-conforming.

The federal lever: ACA-compliant plans must have an exception process per 45 CFR §156.122. If UHC's denial doesn't reference the exception process by name, the appeal can argue procedural defect. ERISA §503's 72-hour expedited path applies for fills near-empty under 29 CFR §2560.503-1(f)(2)(i).

For self-funded UHC ERISA plans, 29 CFR §2560.503-1(g)(1)(iv) requires UHC to disclose all relevant documents on appeal request — demand the OptumRx Drug Coverage Determination policy that supports the tier classification.

Closing tactical tip: include the patient's specific symptom recurrence pattern on the formulary alternative — "patient experienced severe injection-site reactions on Saxenda starting [date], discontinued [date], symptoms resolved within 14 days of switching to Wegovy" — UHC's reviewers respond to specific symptom-medication causation chains.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other UnitedHealthcare appeals

Other insurers on Semaglutide

Other denial reasons for UnitedHealthcare Semaglutide

denied as not medically necessary denied for failing step therapy denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-09. Editorial standards: denialhelp.com/authors.